FDA blesses combo use of GSK's Mekinist, Tafinlar in melanoma

After having a banner year in 2013 – winning the most approvals in the US of new molecular entities (NMEs) –GlaxoSmithKline started out 2014 by gaining the FDA's blessing to market Mekinist (trametinib) and Tafinlar (dabrafenib) for use in combination to treat metastatic or unresectable melanoma.